Qazaq Institute of Innovative Medicine, Regenerative Medicine Division, Cell and Gene Therapy Department, Astana 020000, Kazakhstan.
Int J Mol Sci. 2023 Dec 23;25(1):249. doi: 10.3390/ijms25010249.
The prevalence of autologous blood transfusions (ABTs) presents a formidable challenge in maintaining fair competition in sports, as it significantly enhances hemoglobin mass and oxygen capacity. In recognizing ABT as a prohibited form of doping, the World Anti-Doping Agency (WADA) mandates stringent detection methodologies. While current methods effectively identify homologous erythrocyte transfusions, a critical gap persists in detecting autologous transfusions. The gold standard practice of longitudinally monitoring hematological markers exhibits promise but is encumbered by limitations. Despite its potential, instances of blood doping often go undetected due to the absence of definitive verification processes. Moreover, some cases remain unpenalized due to conservative athlete-sanctioning approaches. This gap underscores the imperative need for a more reliable and comprehensive detection method capable of unequivocally differentiating autologous transfusions, addressing the challenges faced in accurately identifying such prohibited practices. The development of an advanced detection methodology is crucial to uphold the integrity of anti-doping measures, effectively identifying and penalizing instances of autologous blood transfusion. This, in turn, safeguards the fairness and equality essential to competitive sports. Our review tackles this critical gap by harnessing the potential of microRNAs in ABT doping detection. We aim to summarize alterations in the total microRNA profiles of erythrocyte concentrates during storage and explore the viability of observing these changes post-transfusion. This innovative approach opens avenues for anti-doping technologies and commercialization, positioning it as a cornerstone in the ongoing fight against doping in sports and beyond. The significance of developing a robust detection method cannot be overstated, as it ensures the credibility of anti-doping efforts and promotes a level playing field for all athletes.
自身输血(ABTs)的流行给体育比赛中的公平竞争带来了巨大的挑战,因为它显著提高了血红蛋白质量和氧气容量。世界反兴奋剂机构(WADA)将自身输血视为一种被禁止的兴奋剂形式,因此要求采用严格的检测方法。虽然目前的方法能够有效地识别同源红细胞输血,但在检测自身输血方面仍存在一个关键的差距。通过纵向监测血液学标志物的黄金标准实践具有一定的前景,但也受到限制。尽管存在潜力,但由于缺乏明确的验证过程,血液兴奋剂的实例往往未被发现。此外,由于对运动员的制裁方法较为保守,一些情况仍未受到处罚。这种差距突显了需要一种更可靠和全面的检测方法来区分自身输血的紧迫性,以应对准确识别此类被禁止做法所面临的挑战。开发一种先进的检测方法对于维护反兴奋剂措施的完整性至关重要,因为这种方法可以有效地识别和处罚自身输血的实例。这反过来又保护了竞技体育所必需的公平和平等。我们的综述利用了 microRNAs 在自身输血兴奋剂检测中的潜力,旨在总结红细胞浓缩物在储存过程中总 microRNA 谱的变化,并探讨观察这些变化在输血后的可行性。这种创新方法为反兴奋剂技术和商业化开辟了道路,使其成为体育界乃至更广泛范围内打击兴奋剂斗争的基石。开发一种强大的检测方法的重要性怎么强调都不为过,因为它确保了反兴奋剂工作的可信度,并为所有运动员创造了公平的竞争环境。